---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-021833"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2026-06-26T20:07:23+00:00"
generated_at: "2026-06-26T20:08:29.954680+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxart: BARDA modifies COVID-19 trial award to ~$345M; releases $29M for data analysis

## Summary
- Total BARDA funding reduced ~$116M to ~$345M after 50% participant reduction due to partial termination in Aug 2025.
- Modification releases ~$29M for trial completion and exploratory safety/efficacy analyses.
- Vaxart plans to report 12-month data from 400-participant sentinel cohort in coming weeks; main cohort (5,085) data in H1 2027.
- CEO states modification is necessary step to unblinding and reporting first data set.

## SEC filing metadata
- accession: 0001437749-26-021833
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2026-06-26T20:07:23+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774926021833/0001437749-26-021833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774926021833/vxrt20260626_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-021833
- JSON: https://secwatch.observer/filing/0001437749-26-021833.json
- Plain text: https://secwatch.observer/filing/0001437749-26-021833.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.